$31.095
+1.894 (+6.09%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
¿Debería comprar acciones de IRulya Therapeutics Inc.?
IRulya Therapeutics Inc is not a good buy right now due to its significant financial losses and weak performance indicators. The stock is currently priced at 31.09, but it has a forward P/E of 0 and a negative EPS estimate of -0.8300 for the upcoming earnings report. Additionally, the company has reported a net income loss of -39,458,000 for Q4 2025, indicating ongoing financial struggles. The main risk is its declining current ratio, which has fallen to 0.53, suggesting potential liquidity issues.
IRLA cerró en $31.09 el Friday, tras subir +6.09%
IRulya Therapeutics Inc. (IRLA) last closed at $31.0949993, gaining +6.09%. These facts feed the 1-day and 1-week IRLA price prediction above.
Factores de la previsión
Los factores de la previsión de IRulya Therapeutics Inc. (IRLA) combinan patrones gráficos similares, estacionalidad y medias móviles.
Seasonality
Bearish
Análisis de estacionalidad de IRLA
Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.